论文部分内容阅读
Objective :The authors evaluated the effects of intravenous patient controlled analgesia(PCIA)using hydromorphone,sufentanil or oxycodone on cancer pain management and pain-related complications.Methods :Patients assigned to receive PCIA between Jan 2015 and Dec 2016 were selected for this study.After reviewed medical records,we verified if hydromorphone,sufentanil or oxycodone for PCIA could be equally provide effective pain relief.A numeric rating scale(NRS)of cancer pain was applied before PCIA,at 4 hours after PCIA and the discontinuation of PCIA.Secondary,the incidence of clinical side effects that can be associated to PCIA were observed.Results :A total of 85 medical records were reviewed.PCIA with hydromorphone(n=30),sufentanil(n=34)or oxycodone(n=21)was used for cancer pain management.PCIA successfully improved pain control in 97.7%of the patients.The most common side effects were constipation(11.8%),nausea(8.2%)and sedation(5.9%).Drug addiction,delirium or respiratory depression associated with PCIA were not reported in this case series study.No significant inter-group difference was observed in NRS at any of the above-mentioned time points.There was no significant difference of analgesic effect among the hydromorphone,sufentanil or oxycodone.Conclusion :PCIA provided timely,safe and useful analgesia for patients with advanced cancer pain and may be useful to help titration of opioids,manage severe breakthrough pain,and weaning to oral analgesia.There was no significant difference of analgesic effect and side effect among the hydromorphone,sufentanil and oxycodone.